At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,794 enrolled
Drug / intervention
IL-YANG Quadrivalent Influenza Vaccine +2 morebiological
Likely dose
IL-YANG Quadrivalent Influenza Vaccine 0.5mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III Study to Investigate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' After Intramuscular Administration in Healthy Adult Subjects
In Brief
A Phase 3 clinical trial evaluating IL-YANG Quadrivalent Influenza Vaccine, IL-YANG Flu Vaccine Prefilled Syringe, and 1 other intervention for Influenza. Completed, enrolled 1,794 participants.
Detailed Summary
This study evaluates the immunogenicity and safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' in healthy male and female adults at the age of 19 or older.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartOct 2015
Primary CompletionJan 2016
First PostedFeb 2016
Study CompletionJun 2016
TodayJul 2026
First PostedFeb 9, 2016
Enrollment StartOct 1, 2015
Primary CompletionJan 1, 2016
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.4 years ago
Interventions
IL-YANG Quadrivalent Influenza Vaccinebiological
A single 0.5mL dose administrated as an intramuscular injection.
IL-YANG Flu Vaccine Prefilled Syringebiological
A single 0.5mL dose administrated as an intramuscular injection.
IL-YANG Trivalent Influenza Vaccinebiological
A single 0.5mL dose administrated as an intramuscular injection.